AGMB
Agomab Therapeutics NV
$9.61
-2.73%
$473.3M
No data for this timeframe.
Vol
Market Cap$473.3M
Cap SizeSmall Cap
Inst. Holders10 funds
Inst. Value$37.3M
Inst. Activity2 buys / 0 sells
SEC Reports1
Press Releases3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. C9·CIK 0002020932·Prev Close $9.88
Recent Activity
Apr 24, 2026
SEC
Agomab Therapeutics reported its 2025 financial results and provided a 2026 outlook, highlighting a $208 million IPO tha
6-K — Impact 8/10
Inst.
FEDERATED HERMES, INC. — NEW
1,618,000 shares ($17.0M)
Inst.
FMR LLC — NEW
1,458,677 shares ($15.3M)
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: AGMB-129 (Phase 2)
Trial: STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fi
May 27, 2026
Press
Agomab Therapeutics held its Annual General Meeting on May 26, 2026. The press release announces the meeting results but
Impact 2/10
May 14, 2026
Press
Agomab Therapeutics announced that management will participate in upcoming industry and investor conferences. This is a
Impact 2/10
Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$32.00 (Mar 2026)
Current $9.61
Low $28.00
Median $32.00
High $36.00
3 analysts
$28.00
$36.00
Analyst Ratings
4Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 3, 2026 | Leerink Partners | INITIATE | Outperform |
| Mar 3, 2026 | JP Morgan | INITIATE | Overweight |
| Mar 3, 2026 | Morgan Stanley | INITIATE | Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.41 ▲ +19.8% | $-0.46 — $-0.37 | 2 | |
| Next Q | $-0.39 ▲ +0.8% | $-0.40 — $-0.38 | 2 | |
| Current FY | $-1.83 ▲ +1.2% | $-2.05 — $-1.62 | 99% YoY | 2 |
| Next FY | $-2.00 ▼ -1.9% | $-2.45 — $-1.55 | -9% YoY | 2 |
Latest Reports
NEUTRAL
Press
2/10
Agomab Therapeutics held its Annual General Meeting on May 26, 2026. The press release announces the meeting results but
May 27, 2026
BULLISH
6-K
8/10
Agomab Therapeutics reported its 2025 financial results and provided a 2026 outlook, highlighting a $208 million IPO tha
Apr 24, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FEDERATED HERMES, INC. | $17.0M | NEW |
| FMR LLC | $15.3M | NEW |
| LMR Partners LLP | $3.1M | — |
| Alyeska Investment Group, L.P. | $786.8K | — |
| GOLDMAN SACHS GROUP INC | $374.9K | — |
10 institutional holders with $37.3M total value (3,578,734 shares) as of 2026-Q1. Top holders: FEDERATED, FMR, LMR. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FEDERATED HERMES, INC. | 1,618,000 | $17.0M | 45.5% | NEW |
| 2 | FMR LLC | 1,458,677 | $15.3M | 41.0% | NEW |
| 3 | LMR Partners LLP | 300,000 | $3.1M | 8.4% | — |
| 4 | Alyeska Investment Group, L.P. | 75,000 | $786.8K | 2.1% | — |
| 5 | GOLDMAN SACHS GROUP INC | 35,739 | $374.9K | 1.0% | — |
| 6 | CITADEL ADVISORS LLC | 35,000 | $367.1K | 1.0% | — |
| 7 | D. E. Shaw & Co., Inc. | 15,326 | $160.8K | 0.4% | — |
| 8 | TWO SIGMA INVESTMENTS, LP | 14,241 | $149.4K | 0.4% | — |
| 9 | MORGAN STANLEY | 3,025 | $31.7K | 0.1% | — |
| 10 | HRT FINANCIAL LP | 23,726 | $248.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FEDERATED HERMES, INC. | NEW | — | 1,618,000 | — | $17.0M | 2026-Q1 |
| FMR LLC | NEW | — | 1,458,677 | — | $15.3M | 2026-Q1 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 0 neutral. Avg impact: 8.0/10.
NEUTRAL
2/10
Agomab Therapeutics held its Annual General Meeting on May 26, 2026. The press release announces the
May 27, 2026
NEUTRAL
2/10
Agomab Therapeutics announced that management will participate in upcoming industry and investor con
May 14, 2026
NEUTRAL
5/10
AgomAb Therapeutics announced the issuance of a U.S. patent (No. 12,577,230) covering the compositio
Mar 26, 2026
Historical analyst distribution (last covering-analyst action Mar 2026): 90% buy across 10 analysts — 4 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$32.00 mean target (Mar 2026)
$28.00 Low
$36.00 High
| Metric | Value |
|---|---|
| Current Price | $9.61 |
| Target Low | $28.00 |
| Target Mean | $32.00 |
| Target Median | $32.00 |
| Target High | $36.00 |
| # Analysts | 3 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$-0.41 | $-0.46 | $-0.37 | — | +19.8% | 1↑ 0↓ | $0.0B | — | 2 |
| Next Q 2026-06-30 |
$-0.39 | $-0.40 | $-0.38 | — | +0.8% | 1↑ 1↓ | $0.0B | — | 2 |
| Current FY 2026-12-31 |
$-1.83 | $-2.05 | $-1.62 | 98.9% | +1.2% | 1↑ 1↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-2.00 | $-2.45 | $-1.55 | -9.0% | -1.9% | 0↑ 2↓ | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.414 | |
| 7d ago | $-0.516 | +0.102 |
| 30d ago | $-0.516 | +0.102 |
| 60d ago | $0.000 | -0.414 |
| 90d ago | $0.000 | -0.414 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 3 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 3, 2026 | Leerink Partners | INITIATE | — | Outperform |
| Mar 3, 2026 | JP Morgan | INITIATE | — | Overweight |
| Mar 3, 2026 | Morgan Stanley | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 3, 2026
Clinical Trial
STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: AGMB-129 (Phase 2)
Trial: STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease
Sponsor: Agomab Spain
May 27, 2026
announcement
Agomab Announces Results of Annual General Meeting
Agomab Therapeutics NV (Nasdaq: AGMB) today announced the results of its Annual General Meeting (AGM) held on Tuesday, May 26, 2026.
May 14, 2026
announcement
Agomab to Participate in Upcoming Conferences
Agomab Therapeutics today announced that members of managment will participate in several upcoming industry and investor conferences.
Apr 23, 2026
earnings
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
Agomab Therapeutics NV today reported financial results for the full year period ended December 31, 2025, and confirmed its outlook for 2026.
Mar 26, 2026
announcement
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
Agomab today announced that the USPTO granted a patent covering the composition of matter of AGMB-447.
Feb 10, 2026
short_interest
FTD: AGMB — 51,351 shares ($0.8M) failed to deliver
Settlement: 20260210, Price: $15.61, FTD Value: $801,589.11, AGOMAB THERAPEUTICS NV
Feb 9, 2026
short_interest
FTD: AGMB — 166,097 shares ($2.4M) failed to deliver
Settlement: 20260209, Price: $14.65, FTD Value: $2,433,321.05, AGOMAB THERAPEUTICS NV